Home Tags SABCS

Tag: SABCS

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

Phase I Study of Single Agent ZW25 Continues to Show Clinical...

Data covering the completed dose escalation portion of its Phase I study of ZW25 (Zymeworks) , a novel Azymetric™ bispecific antibody targeting two distinct...

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer...

Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in December...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

XMT-1522 Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast...

Positive preclinical data for Mersana Therapeutics'  lead product candidate, XMT-1522, demonstrates significant anti-cancer activity in both HER2-positive and HER2 low-expressing tumor models refractory to...

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...

FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In...

Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the Roche's trastuzumab-DM1 (T-DM1) Biologics...